321 HARRISON AVENUE, BOSTON, MA
Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
SVP Edmund Dunn Retirement; Matthew Bowen Named Successor
Announces Pricing of $300 Million Underwritten Public Offering
Investor Presentation
Monte Rosa Therapeutics Terminates ATM Prospectus Effective January 7, 2026
Announces Third Quarter 2025 Financial Results and Business Updates
Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Submission Upload
Correspondence